Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Watson Launches Generic Zyban

This article was originally published in The Pink Sheet Daily

Executive Summary

Watson launched its "authorized" generic of GlaxoSmithKline's Zyban (bupropion 150 mg) on May 28

You may also be interested in...



Zyban Generics Enter Market; Impax/Teva Launch After Andrx Surrenders Exclusivity

Andrx will share in the profits of Impax/Teva’s bupropion 150 mg for smoking cessation for six months. Relinquishment of first-to-file rights mirrors Andrx’ earlier decision to give up exclusivity on Wellbutrin SR.

Cyramza First-Line Lung Cancer Bid Raises Clinical Practice Questions

Lilly is positioning the ramucirumab/erlotinib combination as a first-line alternative for EGFR-positive non-small cell lung cancer that preserves AstraZeneca’s Tagrisso for second-line use; advisory committee members vote 6-5 for expanded indication but express skepticism about adoption.

US FDA Divided On Expanded Access Requests For Off-Label Use Of Approved Drugs

Agency’s clinical experts favor granting access under regulations intended for investigational drugs but ‘lawyers want consistency under the law,’ FDA’s Woodcock says; use of the expanded access pathway for approved agents is generally unnecessary but may provide sponsors with some regulatory cover, external experts say.

Topics

UsernamePublicRestriction

Register

PS059635

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel